Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

STEPHANIE V BLANK

Allopathic & Osteopathic Physicians Obstetrics & Gynecology Gynecologic Oncology

NPI
1043211626
CMS profile
46868
Location
NEW YORK, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$37.23

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $37.23 1

By paying entity

PY2022 · entire year · sorted by reported total

Paying entityAmountRecords
GlaxoSmithKline, LLC. $37.23 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

STEPHANIE V BLANK

NPI 1043211626 · CMS profile ID 46868

Allopathic & Osteopathic Physicians / Obstetrics & Gynecology / Gynecologic Oncology

NEW YORK, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1043211626?year=2022&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
STEPHANIE V BLANK, NPI 1043211626, CMS profile ID 46868. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1043211626?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). STEPHANIE V BLANK, NPI 1043211626, CMS profile ID 46868. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1043211626?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
STEPHANIE V BLANK, NPI 1043211626, CMS profile ID 46868, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1043211626?year=2022&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $37.23 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
GlaxoSmithKline, LLC. $37.2309/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944868715 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $23.98 2
PY2021 $86.27 2
PY2022 $37.23 1
PY2025 $153.17 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2021, 2022, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2021 , PY2022 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $226,900.10 37
PY2024 Principal investigator $170,088.03 42
PY2023 Principal investigator $268,544.71 34
PY2022 Principal investigator $532,628.40 36
PY2021 Recipient $460.98 2
PY2021 Principal investigator $559,085.02 64
PY2020 Principal investigator $916,005.72 160
PY2019 Principal investigator $645,377.42 103

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

160 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Seagen Inc. $895.00 12/23/2020 Non-covered Recipient Entity
MOUNT SINAI MEDICAL CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen No dispute reported 06/30/2026 733452217
Principal investigator 1 Seagen Inc. $14,805.45 12/23/2020 Non-covered Recipient Entity
MOUNT SINAI MEDICAL CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen No dispute reported 06/30/2026 733452645
Principal investigator 1 Merck Sharp & Dohme Corporation $14,541.30 12/22/2020 Non-covered Recipient Entity
THE BLAVATNIK FAMILY CHELSEA MEDICAL CENTER AT MOUNT SINAI
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740801743
Principal investigator 1 Genentech, Inc. $950.00 12/18/2020 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
GLOBAL RANDOMIZED PHASE II STUDY WITH REGISTRATIONAL POTENTIAL IN 2L PD L1 CERVICAL CANCER No dispute reported 06/30/2026 743036335
Principal investigator 1 Seagen Inc. $895.00 12/16/2020 Non-covered Recipient Entity
MOUNT SINAI MEDICAL CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen No dispute reported 06/30/2026 733452213
Principal investigator 1 GlaxoSmithKline, LLC. $5,956.20 12/15/2020 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA No dispute reported 06/30/2026 734914747
Principal investigator 1 GlaxoSmithKline, LLC. $18,301.00 12/15/2020 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA No dispute reported 06/30/2026 734927163
Principal investigator 1 Merck Sharp & Dohme Corporation $895.00 12/10/2020 Non-covered Recipient Entity
THE BLAVATNIK FAMILY CHELSEA MEDICAL CENTER AT MOUNT SINAI
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740798557
Principal investigator 1 Merck Sharp & Dohme Corporation $895.00 12/10/2020 Non-covered Recipient Entity
THE BLAVATNIK FAMILY CHELSEA MEDICAL CENTER AT MOUNT SINAI
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740798559
Principal investigator 1 Merck Sharp & Dohme Corporation $1,810.48 12/10/2020 Non-covered Recipient Entity
THE BLAVATNIK FAMILY CHELSEA MEDICAL CENTER AT MOUNT SINAI
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740801746
Principal investigator 1 Merck Sharp & Dohme Corporation $10,640.70 12/10/2020 Non-covered Recipient Entity
THE BLAVATNIK FAMILY CHELSEA MEDICAL CENTER AT MOUNT SINAI
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740802019
Principal investigator 1 Merck Sharp & Dohme Corporation $895.00 12/10/2020 Non-covered Recipient Entity
THE BLAVATNIK FAMILY CHELSEA MEDICAL CENTER AT MOUNT SINAI
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740802021
Principal investigator 1 Merck Sharp & Dohme Corporation $895.00 12/10/2020 Non-covered Recipient Entity
THE BLAVATNIK FAMILY CHELSEA MEDICAL CENTER AT MOUNT SINAI
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740802023
Principal investigator 1 Merck Sharp & Dohme Corporation $895.00 12/10/2020 Non-covered Recipient Entity
THE BLAVATNIK FAMILY CHELSEA MEDICAL CENTER AT MOUNT SINAI
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740802025
Principal investigator 1 Merck Sharp & Dohme Corporation $895.00 12/10/2020 Non-covered Recipient Entity
THE BLAVATNIK FAMILY CHELSEA MEDICAL CENTER AT MOUNT SINAI
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740802027
Principal investigator 1 GlaxoSmithKline, LLC. $7,364.00 12/08/2020 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA No dispute reported 06/30/2026 734927135
Principal investigator 1 Merck Sharp & Dohme Corporation $26,055.96 12/03/2020 Non-covered Recipient Entity
MOUNT SINAI CHELSEA
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab MK-3475 Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer KEYNOTE-826 No dispute reported 06/30/2026 740783595
Principal investigator 1 Merck Sharp & Dohme Corporation $18,612.45 11/25/2020 Non-covered Recipient Entity
THE BLAVATNIK FAMILY CHELSEA MEDICAL CENTER AT MOUNT SINAI
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740802017
Principal investigator 1 GlaxoSmithKline, LLC. $5,859.00 11/24/2020 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA No dispute reported 06/30/2026 734924447
Principal investigator 1 Merck Sharp & Dohme Corporation $13,027.98 11/24/2020 Non-covered Recipient Entity
THE BLAVATNIK FAMILY CHELSEA MEDICAL CENTER AT MOUNT SINAI
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740798563
Principal investigator 1 Merck Sharp & Dohme Corporation $1,845.96 11/24/2020 Non-covered Recipient Entity
THE BLAVATNIK FAMILY CHELSEA MEDICAL CENTER AT MOUNT SINAI
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740798567
Principal investigator 1 Genentech, Inc. $4,832.50 11/23/2020 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
GLOBAL RANDOMIZED PHASE II STUDY WITH REGISTRATIONAL POTENTIAL IN 2L PD L1 CERVICAL CANCER No dispute reported 06/30/2026 743036301
Principal investigator 1 Genentech, Inc. $4,592.62 11/19/2020 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM No dispute reported 06/30/2026 743035827
Principal investigator 1 Genentech, Inc. $2,523.00 11/19/2020 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM No dispute reported 06/30/2026 743035833
Principal investigator 1 Seagen Inc. $895.00 11/18/2020 Non-covered Recipient Entity
MOUNT SINAI MEDICAL CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen No dispute reported 06/30/2026 733452207
Principal investigator 1 GlaxoSmithKline, LLC. $1,088.00 11/17/2020 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA No dispute reported 06/30/2026 734920939
Principal investigator 1 Merck Sharp & Dohme Corporation $1,925.00 11/13/2020 Non-covered Recipient Entity
MOUNT SINAI CHELSEA
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab MK-3475 Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer KEYNOTE-826 No dispute reported 06/30/2026 740783505
Principal investigator 1 Seagen Inc. $895.00 11/11/2020 Non-covered Recipient Entity
MOUNT SINAI MEDICAL CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen No dispute reported 06/30/2026 733452203
Principal investigator 1 GlaxoSmithKline, LLC. $2,657.00 11/10/2020 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA No dispute reported 06/30/2026 734919925
Principal investigator 1 GlaxoSmithKline, LLC. $950.00 11/03/2020 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA No dispute reported 06/30/2026 734928993
Principal investigator 1 Seagen Inc. $315.90 11/03/2020 Non-covered Recipient Entity
MOUNT SINAI MEDICAL CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen No dispute reported 06/30/2026 733452193
Principal investigator 1 Seagen Inc. $895.00 11/03/2020 Non-covered Recipient Entity
MOUNT SINAI MEDICAL CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen No dispute reported 06/30/2026 733452197
Principal investigator 1 Seagen Inc. $1,189.88 11/03/2020 Non-covered Recipient Entity
MOUNT SINAI MEDICAL CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen No dispute reported 06/30/2026 733452639
Principal investigator 1 Seagen Inc. $1,350.00 11/03/2020 Non-covered Recipient Entity
MOUNT SINAI MEDICAL CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen No dispute reported 06/30/2026 733452641
Principal investigator 1 Merck Sharp & Dohme Corporation $895.00 10/28/2020 Non-covered Recipient Entity
MOUNT SINAI CHELSEA
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab MK-3475 Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer KEYNOTE-826 No dispute reported 06/30/2026 740783509
Principal investigator 1 Merck Sharp & Dohme Corporation $895.00 10/28/2020 Non-covered Recipient Entity
MOUNT SINAI CHELSEA
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab MK-3475 Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer KEYNOTE-826 No dispute reported 06/30/2026 740783553
Principal investigator 1 Genentech, Inc. $31,313.51 10/26/2020 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
GLOBAL RANDOMIZED PHASE II STUDY WITH REGISTRATIONAL POTENTIAL IN 2L PD L1 CERVICAL CANCER No dispute reported 06/30/2026 743036245
Principal investigator 1 Genentech, Inc. $9,245.00 10/26/2020 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
GLOBAL RANDOMIZED PHASE II STUDY WITH REGISTRATIONAL POTENTIAL IN 2L PD L1 CERVICAL CANCER No dispute reported 06/30/2026 743036253
Principal investigator 1 Merck Sharp & Dohme Corporation $337.50 10/23/2020 Non-covered Recipient Entity
MOUNT SINAI CHELSEA
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab MK-3475 Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer KEYNOTE-826 No dispute reported 06/30/2026 740783507
Principal investigator 1 GlaxoSmithKline, LLC. $5,420.70 10/20/2020 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA No dispute reported 06/30/2026 734910681
Principal investigator 1 Merck Sharp & Dohme Corporation $15,732.90 10/20/2020 Non-covered Recipient Entity
THE BLAVATNIK FAMILY CHELSEA MEDICAL CENTER AT MOUNT SINAI
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740801735
Principal investigator 1 Merck Sharp & Dohme Corporation $3,747.60 10/20/2020 Non-covered Recipient Entity
THE BLAVATNIK FAMILY CHELSEA MEDICAL CENTER AT MOUNT SINAI
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740801739
Principal investigator 1 Seagen Inc. $315.90 10/20/2020 Non-covered Recipient Entity
MOUNT SINAI MEDICAL CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen No dispute reported 06/30/2026 733452187
Principal investigator 1 Merck Sharp & Dohme Corporation $1,845.96 10/15/2020 Non-covered Recipient Entity
THE BLAVATNIK FAMILY CHELSEA MEDICAL CENTER AT MOUNT SINAI
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740798565
Principal investigator 1 Merck Sharp & Dohme Corporation $13,027.98 10/15/2020 Non-covered Recipient Entity
THE BLAVATNIK FAMILY CHELSEA MEDICAL CENTER AT MOUNT SINAI
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740798735
Principal investigator 1 Merck Sharp & Dohme Corporation $1,000.00 10/13/2020 Non-covered Recipient Entity
THE BLAVATNIK FAMILY CHELSEA MEDICAL CENTER AT MOUNT SINAI
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740801731
Principal investigator 1 Merck Sharp & Dohme Corporation $9,139.50 10/07/2020 Non-covered Recipient Entity
MOUNT SINAI CHELSEA
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab MK-3475 Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer KEYNOTE-826 No dispute reported 06/30/2026 740783545
Principal investigator 1 Seagen Inc. $3,031.60 10/07/2020 Non-covered Recipient Entity
MOUNT SINAI MEDICAL CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen No dispute reported 06/30/2026 733452643
Principal investigator 1 Merck Sharp & Dohme Corporation $19,541.97 10/05/2020 Non-covered Recipient Entity
MOUNT SINAI CHELSEA
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab MK-3475 Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer KEYNOTE-826 No dispute reported 06/30/2026 740783593
Principal investigator 1 Genentech, Inc. $750.00 10/01/2020 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM No dispute reported 06/30/2026 743035813
Principal investigator 1 Genentech, Inc. $855.00 10/01/2020 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM No dispute reported 06/30/2026 743035823
Principal investigator 1 Merck Sharp & Dohme Corporation $11,415.80 09/29/2020 Non-covered Recipient Entity
THE BLAVATNIK FAMILY CHELSEA MEDICAL CENTER AT MOUNT SINAI
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740801391
Principal investigator 1 Merck Sharp & Dohme Corporation $1,000.00 09/22/2020 Non-covered Recipient Entity
THE BLAVATNIK FAMILY CHELSEA MEDICAL CENTER AT MOUNT SINAI
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740801387
Principal investigator 1 Seagen Inc. $4,776.30 09/22/2020 Non-covered Recipient Entity
MOUNT SINAI MEDICAL CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen No dispute reported 06/30/2026 733452165
Principal investigator 1 GlaxoSmithKline, LLC. $10,233.00 09/15/2020 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA No dispute reported 06/30/2026 734910919
Principal investigator 1 Merck Sharp & Dohme Corporation $25,975.35 09/10/2020 Non-covered Recipient Entity
THE BLAVATNIK FAMILY CHELSEA MEDICAL CENTER AT MOUNT SINAI
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740801727
Principal investigator 1 GlaxoSmithKline, LLC. $550.00 09/09/2020 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA No dispute reported 06/30/2026 734911747
Principal investigator 1 Genentech, Inc. $3,364.00 08/31/2020 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM No dispute reported 06/30/2026 743035805
Principal investigator 1 Genentech, Inc. $3,342.62 08/27/2020 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM No dispute reported 06/30/2026 743035797
Principal investigator 1 GlaxoSmithKline, LLC. $4,385.70 08/25/2020 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA No dispute reported 06/30/2026 734906941
Principal investigator 1 Merck Sharp & Dohme Corporation $860.85 08/22/2020 Non-covered Recipient Entity
THE BLAVATNIK FAMILY CHELSEA MEDICAL CENTER AT MOUNT SINAI
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740801383
Principal investigator 1 Merck Sharp & Dohme Corporation $98.02 08/20/2020 Non-covered Recipient Entity
MOUNT SINAI CHELSEA
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab MK-3475 Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer KEYNOTE-826 No dispute reported 06/30/2026 740783501
Principal investigator 1 Merck Sharp & Dohme Corporation $68.00 08/07/2020 Non-covered Recipient Entity
MOUNT SINAI CHELSEA
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab MK-3475 Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer KEYNOTE-826 No dispute reported 06/30/2026 740783503
Principal investigator 1 Merck Sharp & Dohme Corporation $26,055.96 08/06/2020 Non-covered Recipient Entity
THE BLAVATNIK FAMILY CHELSEA MEDICAL CENTER AT MOUNT SINAI
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740798561
Principal investigator 1 GlaxoSmithKline, LLC. $4,330.00 08/04/2020 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA No dispute reported 06/30/2026 734913555
Principal investigator 1 Seagen Inc. $895.00 08/04/2020 Non-covered Recipient Entity
MOUNT SINAI MEDICAL CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen No dispute reported 06/30/2026 733452149
Principal investigator 1 Seagen Inc. $4,172.85 08/04/2020 Non-covered Recipient Entity
MOUNT SINAI MEDICAL CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen No dispute reported 06/30/2026 733452171
Principal investigator 1 Merck Sharp & Dohme Corporation $19,541.97 08/03/2020 Non-covered Recipient Entity
MOUNT SINAI CHELSEA
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab MK-3475 Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer KEYNOTE-826 No dispute reported 06/30/2026 740783549
Principal investigator 1 GlaxoSmithKline, LLC. $12,647.00 07/28/2020 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA No dispute reported 06/30/2026 734911539
Principal investigator 1 GlaxoSmithKline, LLC. $28,571.40 07/28/2020 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA No dispute reported 06/30/2026 734916157
Principal investigator 1 Seagen Inc. $4,776.30 07/23/2020 Non-covered Recipient Entity
MOUNT SINAI MEDICAL CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen No dispute reported 06/30/2026 733452159
Principal investigator 1 Merck Sharp & Dohme Corporation $300.00 07/22/2020 Non-covered Recipient Entity
MOUNT SINAI CHELSEA
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab MK-3475 Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer KEYNOTE-826 No dispute reported 06/30/2026 740783455
Principal investigator 1 Merck Sharp & Dohme Corporation $895.00 07/22/2020 Non-covered Recipient Entity
MOUNT SINAI CHELSEA
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab MK-3475 Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer KEYNOTE-826 No dispute reported 06/30/2026 740783459
Principal investigator 1 Merck Sharp & Dohme Corporation $2,000.00 07/21/2020 Non-covered Recipient Entity
THE BLAVATNIK FAMILY CHELSEA MEDICAL CENTER AT MOUNT SINAI
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740800687
Principal investigator 1 Merck Sharp & Dohme Corporation $895.00 07/21/2020 Non-covered Recipient Entity
THE BLAVATNIK FAMILY CHELSEA MEDICAL CENTER AT MOUNT SINAI
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740801031
Principal investigator 1 Merck Sharp & Dohme Corporation $895.00 07/21/2020 Non-covered Recipient Entity
THE BLAVATNIK FAMILY CHELSEA MEDICAL CENTER AT MOUNT SINAI
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740801035
Principal investigator 1 Merck Sharp & Dohme Corporation $337.50 07/17/2020 Non-covered Recipient Entity
MOUNT SINAI CHELSEA
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab MK-3475 Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer KEYNOTE-826 No dispute reported 06/30/2026 740783457
Principal investigator 1 Seagen Inc. $4,050.00 07/15/2020 Non-covered Recipient Entity
MOUNT SINAI MEDICAL CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen No dispute reported 06/30/2026 733452153
Principal investigator 1 Merck Sharp & Dohme Corporation $1,000.00 07/14/2020 Non-covered Recipient Entity
THE BLAVATNIK FAMILY CHELSEA MEDICAL CENTER AT MOUNT SINAI
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740800679
Principal investigator 1 Merck Sharp & Dohme Corporation $895.00 07/09/2020 Non-covered Recipient Entity
THE BLAVATNIK FAMILY CHELSEA MEDICAL CENTER AT MOUNT SINAI
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740801375
Principal investigator 1 Merck Sharp & Dohme Corporation $895.00 07/09/2020 Non-covered Recipient Entity
THE BLAVATNIK FAMILY CHELSEA MEDICAL CENTER AT MOUNT SINAI
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740801379
Principal investigator 1 Merck Sharp & Dohme Corporation $1,925.00 07/07/2020 Non-covered Recipient Entity
THE BLAVATNIK FAMILY CHELSEA MEDICAL CENTER AT MOUNT SINAI
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740800683
Principal investigator 1 Merck Sharp & Dohme Corporation $2,598.02 07/07/2020 Non-covered Recipient Entity
THE BLAVATNIK FAMILY CHELSEA MEDICAL CENTER AT MOUNT SINAI
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740801021
Principal investigator 1 Merck Sharp & Dohme Corporation $843.58 07/07/2020 Non-covered Recipient Entity
THE BLAVATNIK FAMILY CHELSEA MEDICAL CENTER AT MOUNT SINAI
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740801023
Principal investigator 1 Merck Sharp & Dohme Corporation $895.00 07/07/2020 Non-covered Recipient Entity
THE BLAVATNIK FAMILY CHELSEA MEDICAL CENTER AT MOUNT SINAI
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740801041
Principal investigator 1 Merck Sharp & Dohme Corporation $895.00 06/24/2020 Non-covered Recipient Entity
MOUNT SINAI CHELSEA
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab MK-3475 Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer KEYNOTE-826 No dispute reported 06/30/2026 740783411
Principal investigator 1 Seagen Inc. $4,776.30 06/24/2020 Non-covered Recipient Entity
MOUNT SINAI MEDICAL CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen No dispute reported 06/30/2026 733452103
Principal investigator 1 GlaxoSmithKline, LLC. $1,500.00 06/16/2020 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA No dispute reported 06/30/2026 734920367
Principal investigator 1 Merck Sharp & Dohme Corporation $895.00 06/16/2020 Non-covered Recipient Entity
THE BLAVATNIK FAMILY CHELSEA MEDICAL CENTER AT MOUNT SINAI
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740801027
Principal investigator 1 Merck Sharp & Dohme Corporation $5,899.50 06/12/2020 Non-covered Recipient Entity
MOUNT SINAI CHELSEA
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab MK-3475 Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer KEYNOTE-826 No dispute reported 06/30/2026 740783379
Principal investigator 1 Merck Sharp & Dohme Corporation $6,012.50 06/03/2020 Non-covered Recipient Entity
MOUNT SINAI CHELSEA
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab MK-3475 Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer KEYNOTE-826 No dispute reported 06/30/2026 740783409
Principal investigator 1 Seagen Inc. $337.50 06/02/2020 Non-covered Recipient Entity
MOUNT SINAI MEDICAL CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen No dispute reported 06/30/2026 733452097
Principal investigator 1 Genentech, Inc. $18,438.00 05/27/2020 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM No dispute reported 06/30/2026 743035785
Principal investigator 1 Seagen Inc. $550.00 05/20/2020 Non-covered Recipient Entity
MOUNT SINAI MEDICAL CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen No dispute reported 06/30/2026 733452055
Principal investigator 1 GlaxoSmithKline, LLC. $23,141.00 05/12/2020 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA No dispute reported 06/30/2026 734918365
Principal investigator 1 Merck Sharp & Dohme Corporation $26,055.96 05/11/2020 Non-covered Recipient Entity
MOUNT SINAI CHELSEA
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab MK-3475 Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer KEYNOTE-826 No dispute reported 06/30/2026 740783551
Principal investigator 1 Merck Sharp & Dohme Corporation $715.40 05/06/2020 Non-covered Recipient Entity
MOUNT SINAI CHELSEA
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab MK-3475 Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer KEYNOTE-826 No dispute reported 06/30/2026 740783465
Principal investigator 1 Seagen Inc. $1,925.00 05/06/2020 Non-covered Recipient Entity
MOUNT SINAI MEDICAL CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen No dispute reported 06/30/2026 733452049
Principal investigator 1 Genentech, Inc. $13,000.00 05/05/2020 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM No dispute reported 06/30/2026 743035776
Principal investigator 1 GlaxoSmithKline, LLC. $37,779.30 05/05/2020 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA No dispute reported 06/30/2026 734912327
Principal investigator 1 Merck Sharp & Dohme Corporation $480.90 04/30/2020 Non-covered Recipient Entity
MOUNT SINAI CHELSEA
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab MK-3475 Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer KEYNOTE-826 No dispute reported 06/30/2026 740783463
Principal investigator 1 Merck Sharp & Dohme Corporation $2,705.40 04/29/2020 Non-covered Recipient Entity
MOUNT SINAI CHELSEA
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab MK-3475 Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer KEYNOTE-826 No dispute reported 06/30/2026 740783413
Principal investigator 1 Merck Sharp & Dohme Corporation $895.00 04/29/2020 Non-covered Recipient Entity
MOUNT SINAI CHELSEA
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab MK-3475 Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer KEYNOTE-826 No dispute reported 06/30/2026 740783417
Principal investigator 1 Merck Sharp & Dohme Corporation $453.00 04/29/2020 Non-covered Recipient Entity
MOUNT SINAI CHELSEA
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab MK-3475 Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer KEYNOTE-826 No dispute reported 06/30/2026 740783461
Principal investigator 1 Seagen Inc. $1,350.00 04/22/2020 Non-covered Recipient Entity
MOUNT SINAI MEDICAL CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen No dispute reported 06/30/2026 733452011
Principal investigator 1 Seagen Inc. $97,744.05 04/22/2020 Non-covered Recipient Entity
MOUNT SINAI MEDICAL CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen No dispute reported 06/30/2026 733452120
Principal investigator 1 Merck Sharp & Dohme Corporation $19,541.97 04/20/2020 Non-covered Recipient Entity
MOUNT SINAI CHELSEA
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab MK-3475 Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer KEYNOTE-826 No dispute reported 06/30/2026 740783547
Principal investigator 1 Merck Sharp & Dohme Corporation $6,509.10 04/17/2020 Non-covered Recipient Entity
MOUNT SINAI CHELSEA
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab MK-3475 Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer KEYNOTE-826 No dispute reported 06/30/2026 740783415
Principal investigator 1 Merck Sharp & Dohme Corporation $3,240.00 04/15/2020 Non-covered Recipient Entity
MOUNT SINAI CHELSEA
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab MK-3475 Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer KEYNOTE-826 No dispute reported 06/30/2026 740783419
Principal investigator 1 Seagen Inc. $895.00 04/15/2020 Non-covered Recipient Entity
MOUNT SINAI MEDICAL CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen No dispute reported 06/30/2026 733452043
Principal investigator 1 Seagen Inc. $945.00 04/15/2020 Non-covered Recipient Entity
MOUNT SINAI MEDICAL CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen No dispute reported 06/30/2026 733452077
Principal investigator 1 Seagen Inc. $14,500.70 04/15/2020 Non-covered Recipient Entity
MOUNT SINAI MEDICAL CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen No dispute reported 06/30/2026 733452081
Principal investigator 1 Seagen Inc. $202.50 04/15/2020 Non-covered Recipient Entity
MOUNT SINAI MEDICAL CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen No dispute reported 06/30/2026 733452087
Principal investigator 1 Seagen Inc. $675.00 04/15/2020 Non-covered Recipient Entity
MOUNT SINAI MEDICAL CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen No dispute reported 06/30/2026 733452093
Principal investigator 1 EMD Serono, Inc. $675.00 04/14/2020 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK
Study of Avelumab + M6620 + Carboplatin in Poly (Adenosine diphosphate ribose [ADP]-ribose) polymerase inhibitor (PARPi)-resistant Recurrent Ovarian Cancer No dispute reported 06/30/2026 749600295
Principal investigator 1 EMD Serono, Inc. $2,025.00 04/14/2020 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK
Study of Avelumab + M6620 + Carboplatin in Poly (Adenosine diphosphate ribose [ADP]-ribose) polymerase inhibitor (PARPi)-resistant Recurrent Ovarian Cancer No dispute reported 06/30/2026 749611057
Principal investigator 1 EMD Serono, Inc. $2,500.00 04/14/2020 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK
Study of Avelumab + M6620 + Carboplatin in Poly (Adenosine diphosphate ribose [ADP]-ribose) polymerase inhibitor (PARPi)-resistant Recurrent Ovarian Cancer No dispute reported 06/30/2026 749612627
Principal investigator 1 GlaxoSmithKline, LLC. $4,501.80 04/07/2020 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA No dispute reported 06/30/2026 734928803
Principal investigator 1 Genentech, Inc. $2,092.62 04/02/2020 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM No dispute reported 06/30/2026 743035771
Principal investigator 1 Genentech, Inc. $5,750.00 03/30/2020 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM No dispute reported 06/30/2026 743035765
Principal investigator 1 Merck Sharp & Dohme Corporation $895.00 03/18/2020 Non-covered Recipient Entity
MOUNT SINAI CHELSEA
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab MK-3475 Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer KEYNOTE-826 No dispute reported 06/30/2026 740783377
Principal investigator 1 Seagen Inc. $895.00 03/18/2020 Non-covered Recipient Entity
MOUNT SINAI MEDICAL CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen No dispute reported 06/30/2026 733452037
Principal investigator 1 Seagen Inc. $400.00 03/18/2020 Non-covered Recipient Entity
MOUNT SINAI MEDICAL CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen No dispute reported 06/30/2026 733452071
Principal investigator 1 GlaxoSmithKline, LLC. $101.98 03/17/2020 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA No dispute reported 06/30/2026 734922313
Principal investigator 1 Merck Sharp & Dohme Corporation $2,189.12 03/09/2020 Non-covered Recipient Entity
MOUNT SINAI CHELSEA
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab MK-3475 Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer KEYNOTE-826 No dispute reported 06/30/2026 740783297
Principal investigator 1 Merck Sharp & Dohme Corporation $895.00 03/09/2020 Non-covered Recipient Entity
MOUNT SINAI CHELSEA
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab MK-3475 Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer KEYNOTE-826 No dispute reported 06/30/2026 740783337
Principal investigator 1 Merck Sharp & Dohme Corporation $2,847.15 03/09/2020 Non-covered Recipient Entity
MOUNT SINAI CHELSEA
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab MK-3475 Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer KEYNOTE-826 No dispute reported 06/30/2026 740783339
Principal investigator 1 Merck Sharp & Dohme Corporation $895.00 03/05/2020 Non-covered Recipient Entity
THE BLAVATNIK FAMILY CHELSEA MEDICAL CENTER AT MOUNT SINAI
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740800671
Principal investigator 1 Seagen Inc. $895.00 03/04/2020 Non-covered Recipient Entity
MOUNT SINAI MEDICAL CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen No dispute reported 06/30/2026 733452131
Principal investigator 1 Genentech, Inc. $11,277.86 03/03/2020 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM No dispute reported 06/30/2026 743035849
Principal investigator 1 Merck Sharp & Dohme Corporation $3,198.15 03/02/2020 Non-covered Recipient Entity
MOUNT SINAI CHELSEA
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab MK-3475 Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer KEYNOTE-826 No dispute reported 06/30/2026 740783293
Principal investigator 1 Merck Sharp & Dohme Corporation $895.00 03/02/2020 Non-covered Recipient Entity
MOUNT SINAI CHELSEA
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab MK-3475 Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer KEYNOTE-826 No dispute reported 06/30/2026 740783333
Principal investigator 1 Merck Sharp & Dohme Corporation $895.00 03/02/2020 Non-covered Recipient Entity
MOUNT SINAI CHELSEA
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab MK-3475 Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer KEYNOTE-826 No dispute reported 06/30/2026 740783335
Principal investigator 1 Merck Sharp & Dohme Corporation $3,198.15 03/02/2020 Non-covered Recipient Entity
MOUNT SINAI CHELSEA
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab MK-3475 Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer KEYNOTE-826 No dispute reported 06/30/2026 740783371
Principal investigator 1 Seagen Inc. $895.00 02/26/2020 Non-covered Recipient Entity
MOUNT SINAI MEDICAL CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen No dispute reported 06/30/2026 733452125
Principal investigator 1 Seagen Inc. $500.00 02/26/2020 Non-covered Recipient Entity
MOUNT SINAI MEDICAL CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen No dispute reported 06/30/2026 733452137
Principal investigator 1 Seagen Inc. $895.00 02/26/2020 Non-covered Recipient Entity
MOUNT SINAI MEDICAL CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen No dispute reported 06/30/2026 733452143
Principal investigator 1 GlaxoSmithKline, LLC. $1,016.68 02/25/2020 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA No dispute reported 06/30/2026 734916315
Principal investigator 1 GlaxoSmithKline, LLC. $9,318.60 02/19/2020 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA No dispute reported 06/30/2026 734913469
Principal investigator 1 Merck Sharp & Dohme Corporation $16,239.36 02/17/2020 Non-covered Recipient Entity
MOUNT SINAI CHELSEA
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab MK-3475 Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer KEYNOTE-826 No dispute reported 06/30/2026 740783555
Principal investigator 1 Merck Sharp & Dohme Corporation $2,844.45 02/14/2020 Non-covered Recipient Entity
MOUNT SINAI CHELSEA
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab MK-3475 Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer KEYNOTE-826 No dispute reported 06/30/2026 740783331
Principal investigator 1 Merck Sharp & Dohme Corporation $151.00 02/12/2020 Non-covered Recipient Entity
MOUNT SINAI CHELSEA
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab MK-3475 Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer KEYNOTE-826 No dispute reported 06/30/2026 740783499
Principal investigator 1 Seagen Inc. $895.00 02/12/2020 Non-covered Recipient Entity
MOUNT SINAI MEDICAL CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen No dispute reported 06/30/2026 733452033
Principal investigator 1 Seagen Inc. $1,350.00 01/29/2020 Non-covered Recipient Entity
MOUNT SINAI MEDICAL CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen No dispute reported 06/30/2026 733452029
Principal investigator 1 Seagen Inc. $1,752.50 01/29/2020 Non-covered Recipient Entity
MOUNT SINAI MEDICAL CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen No dispute reported 06/30/2026 733452061
Principal investigator 1 Seagen Inc. $845.00 01/21/2020 Non-covered Recipient Entity
MOUNT SINAI MEDICAL CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen No dispute reported 06/30/2026 733452023
Principal investigator 1 Seagen Inc. $3,541.05 01/21/2020 Non-covered Recipient Entity
MOUNT SINAI MEDICAL CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen No dispute reported 06/30/2026 733452109
Principal investigator 1 Genentech, Inc. $1,250.00 01/17/2020 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM No dispute reported 06/30/2026 743035841
Principal investigator 1 Seagen Inc. $11,812.50 01/15/2020 Non-covered Recipient Entity
MOUNT SINAI MEDICAL CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen No dispute reported 06/30/2026 733452065
Principal investigator 1 GlaxoSmithKline, LLC. $6,677.10 01/14/2020 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA No dispute reported 06/30/2026 734918211
Principal investigator 1 Merck Sharp & Dohme Corporation $1,234.15 01/09/2020 Non-covered Recipient Entity
THE BLAVATNIK FAMILY CHELSEA MEDICAL CENTER AT MOUNT SINAI
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740800315
Principal investigator 1 Merck Sharp & Dohme Corporation $2,515.05 01/08/2020 Non-covered Recipient Entity
MOUNT SINAI CHELSEA
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab MK-3475 Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer KEYNOTE-826 No dispute reported 06/30/2026 740783329
Principal investigator 1 Merck Sharp & Dohme Corporation $3,030.75 01/08/2020 Non-covered Recipient Entity
MOUNT SINAI CHELSEA
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab MK-3475 Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer KEYNOTE-826 No dispute reported 06/30/2026 740783369
Principal investigator 1 Merck Sharp & Dohme Corporation $525.00 01/08/2020 Non-covered Recipient Entity
MOUNT SINAI CHELSEA
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab MK-3475 Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer KEYNOTE-826 No dispute reported 06/30/2026 740783373
Principal investigator 1 Merck Sharp & Dohme Corporation $8,667.10 01/08/2020 Non-covered Recipient Entity
MOUNT SINAI CHELSEA
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab MK-3475 Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer KEYNOTE-826 No dispute reported 06/30/2026 740783375
Principal investigator 1 Seagen Inc. $845.00 01/08/2020 Non-covered Recipient Entity
MOUNT SINAI MEDICAL CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen No dispute reported 06/30/2026 733452017
Principal investigator 1 Seagen Inc. $23,311.80 01/08/2020 Non-covered Recipient Entity
MOUNT SINAI MEDICAL CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen No dispute reported 06/30/2026 733452115
Principal investigator 1 Merck Sharp & Dohme Corporation $845.00 01/07/2020 Non-covered Recipient Entity
THE BLAVATNIK FAMILY CHELSEA MEDICAL CENTER AT MOUNT SINAI
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740800667
Principal investigator 1 Merck Sharp & Dohme Corporation $525.00 01/07/2020 Non-covered Recipient Entity
THE BLAVATNIK FAMILY CHELSEA MEDICAL CENTER AT MOUNT SINAI
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 740800675
Principal investigator 1 Merck Sharp & Dohme Corporation $1,825.00 01/06/2020 Non-covered Recipient Entity
MOUNT SINAI CHELSEA
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab MK-3475 Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer KEYNOTE-826 No dispute reported 06/30/2026 740783295